Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2026)

Monte Rosa Therapeutics' Revenue history runs 3 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• On a quarterly basis, Revenue fell 94.94% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 97.3% decrease from a year earlier, with the FY2025 full-year figure at $123.7 million, up 63.54% from the prior year.
• Revenue improved to $4.3 million in Q1 2026 per GLUE's latest filing, from $2.8 million in the prior quarter.
• Across five years, Revenue topped out at $150.0 million in Q3 2025 and bottomed at $1.1 million in Q1 2024.
• The 3-year median for Revenue is $9.2 million (2024), against an average of $50.9 million.
• Biggest YoY gain for Revenue was 7882.05% in 2025; the steepest drop was 95.41% in 2025.
• Year by year, Revenue stood at $60.6 million in 2024, then sank by 95.41% to $2.8 million in 2025, then surged by 54.62% to $4.3 million in 2026.
• Per Business Quant, the three latest GLUE Revenue figures stand at $4.3 million (Q1 2026), $2.8 million (Q4 2025), and $150.0 million (Q3 2025).